Shankar Siva: For Kidney Cancer Awareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II
Quoting Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, on X/Twitter:
”For Kidney Cancer Awareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II! Thank you Cancer Australia, The Australian and New Zealand Urogenital and Prostate cancer trials group (ANZUP), Varian. A new radiotherapy standard of care option for inoperable primary kidney cancer.
Excitingly, 100% control rates despite a median size of 4.6cms, and biological aggressiveness with 70% progressing on surveillance (imaging) prior to enrolment. Despite this, recent European Association of Urology (EAU), EAU guidelines confusingly lump TA and SABR together… and caution treating >3cm!
There are >dozen clinical trials of SABR for primary RCC – outlined in The International Stereotactic Radiosurgery Society (ISRS) practice guideline – compared to zero for thermal ablation. The weight of evidence is with SABR, not TA, and is arguably the preferred modality for non-surgical therapy.
Very excited to share this with you!!! Sumanta K. Pal, Toni Choueiri, Brian Shuch, Grant Stewart, Phillip Pierorazio, Todd Morgan, Alexander Kutikov, Sarah P. Psutka, Michael Staehler, IKCC Kidney Cancer, Kidney Cancer. For more information, please follow the thread from ASTRO 2023. Read further.”
Source: Shankar Siva/X
